What is it about?

A new multimodal NEXTAC (Nutrition and Exercise Treatment for Advanced Cancer) program is highly feasible (participation rate of 97%) for elderly patients with advanced pancreatic cancer or non-small-cell lung cancer receiving chemotherapy with excellent compliance (>90% in each component) and few drop outs (only one patient). It is potentially effective to preserve physical function in this population (NEXTAC-ONE study, Trial No. UMIN000023207).

Featured Image

Why is it important?

The multimodal NEXTAC program may roll back the wasting process and put off the disability of elderly cancer patients who have cachectic risks and are receiving concurrent chemotherapy. It will be needed not only to live longer, but also to live a full life. Of course we need good medicine, but also we need dietitian, physiotherapist, and nurses to achieve goal for this population.


The combination of emerging anti-cachectic medications and non-pharmacological interventions will be the next step in this area. Our NEXTAC program would be a good candidate for this combination, because it has no overlapping adverse events and might minimally reduce compliance of combination treatment. Based on the positive results of this NEXTAC-ONE trial, we are currently conducting a prospective multicentre randomized phase II study of early exercise and nutritional interventions for the same population (NEXTAC-TWO study, Trial No. UMIN000028801). We hypothesize that early induction of NEXTAC might maintain physical function and prevent disability in elderly patients with advanced cancer who are at considerable risk of cancer cachexia.

MD. PhD. Tateaki Naito
Shizuoka Cancer Center

Read the Original

This page is a summary of: Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer, Journal of Cachexia Sarcopenia and Muscle, October 2018, Wiley,
DOI: 10.1002/jcsm.12351.
You can read the full text:




The following have contributed to this page